TIRmed Pharma

Developing a next-generation topical treatment of eczema (atopic dermatitis) for mild to moderate symptoms.

  • Healthtech
  • Seed
Location
Stockholm, Sweden
Revenue size
Year founded
2018
Funding raised
EUR 578,000
Founders
Prof. Anna-Lena Spetz Ph.D
Most relevant investors
Almi Invest
Team size
2-10
Website

www.tirmedpharma.com

Problem

10-20% of children and 2-5% of adults are afflicted with atopic dermatitis, common, chronic eczema disease with fluctuating severity. The decline in quality of life is comparable to insulin-dependent diabetes in affected families due to intense itching accompanied with sleep disruption and mood disorders. The scratches and disrupted skin barrier leads to secondary infections that require antibiotic treatments. There is a large unmet need to develop new medications for patients that do not respond to the current anti-itch medication or topical steroids.

SOLUTION

TIRmed Pharma´s product candidate is a chemically stabilized, single-stranded oligonucleotide, which has non-coding and non-complementary sequence. The compound is formulated in a cream aiming for a self-applied and easy to use at-home anti-itch treatment.

KEY CUSTOMERS AND INTERNATIONAL PRESENCE

With a huge population globally suffering from atopic dermatitis, there is a massive potential customer base for the products that will be developed as a result of TIRmed’s research.

Team

TIRmed was founded in 2018 by Professor Anna-Lena Sptez, Ph.D, who has spent 25+ years in immunology research with previous experiences from Karolinska Institutet, Institut Pasteur, and Dana-Farber Cancer Institute, Harvard Medical School.

Unique selling point

TIRmed’s proprietary research and approach represent a novel method to modulate immune responses and ameliorate itch.

Asia Connection

GET IN TOUCH WITH

TIRmed Pharma